Comparing Dopamine, Norepinephrine and Epinephrine for Pulmonary Hypertension Crisis
Compares dopamine, norepinephrine and epinephrine in adults in pulmonary hypertension crisis.
Key facts
- Who runs it
- China National Center for Cardiovascular Diseases
- Where
- Beijing, Guangzhou, and Wuhan, ChinaSee the 3 sites
- Trial code
- Registry title
- Vasopressor Agents in Pulmonary Hypertension Crisis
- Status
- Recruiting
- People taking part
- 75 people, planned
- Started
- 19 Aug 2026
- Expected to end
- 31 Jan 2029
- Type of study
- Interventional, 3 groups
- Treatments tested
- Norepinephrine
- Dopamine
- Epinephrine
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension who are in a pulmonary hypertensive crisis. It compares three drugs: dopamine, norepinephrine and epinephrine.
- Age
- Over 18 years
- Sex
- All sexes can join
- Disease stage
- Confirmed pulmonary arterial hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH), with signs of a pulmonary hypertensive crisis. Diagnosis and treatment must both happen in the hospital.
- Earlier treatment
- Must not be getting dopamine, norepinephrine or epinephrine through a vein at enrollment.
Main reasons for not taking part
- SCAI stage D or stage E
- Pregnancy
- Uncontrolled hyperthyroidism or angle-closure glaucoma
- Allergy to the study drugs
- Current use of MAOI antidepressants or anti-Parkinson drugs, or halogenated general anesthetics such as cyclopropane and halothane
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age > 18 years old
- Signed informed consent form
- Confirmed diagnosis of arterial pulmonary hypertension (PAH) and/or chronic thromboembolic pulmonary hypertension (CTEPH)
- Presenting with manifestations of pulmonary hypertensive crisis
- Receiving both diagnosis and treatment in-hospital
- No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment
Who cannot take part
- Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide)
- Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment
- Hypersensitivity to the study drug
- At SCAI stage D or stage E
- Patients who only receive a diagnosis but no treatment in the hospital
- Uncontrolled hyperthyroidism
- Complicated with angle-closure glaucoma
- Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane
- Pregnancy
Where in China
- Chinese Academy of Medical Sciences, Fuwai HospitalBeijing, ChinaContact: Qing Gu,MDTaking people
- Guangdong Provincial People's HospitalGuangzhou, ChinaContact: Li HuangNot yet recruiting
- Zhongnan Hospital of Wuhan UniversityWuhan, ChinaContact: Gangcheng ZhangNot yet recruiting
About the trial
What the trial wants to find out
Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring
The 3 groups in the trial
- Norepinephrine groupTreatment being tested
The initial dose is 0.02 mg/kg/min of norepinephrine; each dose adjustment (increase or decrease) is 0.02 mg/kg/min of norepinephrine; the maximum dose of norepinephrine is 0.2 mg/kg/min.
Treatment: Norepinephrine
- Dopamine groupTreatment being tested
The initial dose is 2 μg/kg/min of dopamine; each dose adjustment (increase or decrease) is 2 μg/kg/min of dopamine; the maximum dose of dopamine is 20 μg/kg/min.
Treatment: Dopamine
- Epinephrine groupTreatment being tested
The initial dose is 0.02 μg/kg/min of epinephrine; each adjustment (increase or decrease) is 0.02 μg/kg/min of epinephrine; the maximum dose of epinephrine is 0.2 μg/kg/min
Treatment: Epinephrine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring
- Plain-language title
- Comparing Dopamine, Norepinephrine and Epinephrine for Pulmonary Hypertension CrisisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 30 October 2026